NeoTherapeutics Alzheimer's therapy AIT-082 could enter Phase I through NIH by year-end.
Executive Summary
NEOTHERAPEUTICS AIT-082 COULD ENTER PHASE I FOR ALZHEIMER's BY YEAR END under the auspices of the National Institute on Aging's Alzheimer's Disease Cooperative Study Unit, according to a prospectus for NeoTherapeutics' initial public offering. NIA "has committed to fund and conduct two Phase I clinical trials" and is funding, with the National Institute for Mental Health, production of AIT-082 for clinical trials, the prospectus states.